研究单位：[1]Hangzhou ACEA Pharmaceutical Research Co.,Ltd.[2]Cancer Institute and Hospital,Chinese Academy of Medical Sciences[3]Sichuan Cancer Hospital & Institute Chengdu,Sichuan,China,610000[4]West China Hospital,Sichuan University Chengdu,Sichuan,China,610000[5]Tianjin Medical University Cancer Institute & Hospital Tianjin,Tianjin,China,300000[6]The First Affiliated Hospital,Zhejiang University Hangzhou,Zhejiang,China,310000[7]Zhejiang Cancer Hospital Hangzhou,Zhejiang,China,310000[8]Cancer Institute and Hospital,Chinese Academy of Medical Sciences Beijing,China,100021[9]Beijing Cancer Hospital Beijing,Beijing,China,100000[10]Chinese General PLA Hospital Beijing,Beijing,China,100000[11]Peking Union Medical College Hospital Beijing,Beijing,China,100000[12]Xinqiao Hospital Army Medical University Chongqing,Chongqing,China,400000
研究目的：
A Phase III,Open-Label,Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI.
